06th March 2024
We’ve been working with Dr Jay Schneekloth, a leading expert in RNA-targeted drug discovery, to use our MAGNA™ technology to probe the interactions between the PreQ1 bacterial riboswitch and its natural ligand or a synthetic small molecule.
Read More12th February 2024
Paris, France – Depixus CEO Gordon Hamilton Receives The SLAS2024 Ignite Award From Judge Severine Tamas-Lhoustau, CEO Of Novoptim.
Read More11th January 2024
PARIS, France – Interactomics pioneer Depixus has appointed experienced life sciences sales leader, Steve Klose, to the newly created role of Chief Commercial Officer from January 16, 2024. Klose will lead the company’s commercial growth strategy to build a highly effective sales and support organization, strengthening its market presence ahead of the commercial launch of its first laboratory instrument, MAGNA One™, in 2024.
Read More